ClinicalTrials.Veeva

Menu

Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome

Y

Yuzuncu Yıl University

Status and phase

Completed
Phase 4

Conditions

Overactive Bladder Syndrome
Obstructive Sleep Apnea
Overactive Bladder

Treatments

Other: Continuous positive airway pressure therapy (CPAP)
Drug: Tolterodine Tartrate 4 MG

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

In this study, we aim to determine whether combined tolterodine and CPAP therapy is a more effective treatment for patients with OSAS than CPAP treatment only.

Enrollment

60 patients

Sex

Female

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Women older than 18 who underwent polysomnography test with suspicion of OSAS between 01.06.2020-01.01.2022 were enrolled in the study
  • Patients with AHI ≥15 (moderate or severe) and OAB-V8≥8 were considered eligible for the study and randomized in two groups to receive either CPAP treatment only or CPAP treatment with tolterodine tartrate

Exclusion criteria

  • Patients diagnosed with neurological diseases, diabetes mellitus, congestive heart failure, infection, hematuria, urolithiasis, urinary tumors, and urinary retention were excluded from the study. Also, a history of lower urinary tract surgery and medication due to lower urinary tract symptoms were the exclusion criteria.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

CPAP only group
Active Comparator group
Description:
Patients who are going to receive only CPAP treatment for their moderate-to-severe obstructive sleep apnea syndrome (OSAS)
Treatment:
Other: Continuous positive airway pressure therapy (CPAP)
Combined use of CPAP and tolterodine
Active Comparator group
Description:
Patients who are going to receive combined use of CPAP and tolterodine 4mg a day treatment for their OSAS
Treatment:
Other: Continuous positive airway pressure therapy (CPAP)
Drug: Tolterodine Tartrate 4 MG

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems